Patients with Genetic Heart Disease and COVID-19
In these uncertain times, we at the Windland Smith Rice Genetic Heart Rhythm Clinic understand that everyone is worried about the SARS-Cov-2 (coronavirus)-caused COVID-19 and whether it puts patients with genetic heart disease at a higher risk. The following information is meant to provide some guidance for you during this difficult time. This is a rapidly changing situation and we will attempt to keep this information as up-to-date as possible.
FAQs for patients with genetic heart rhythm conditions:
- Am I at higher risk?
- Are there extra precautions I should take?
- What concerns are there over the use of hydroxychloroquine and azithromycin (potential/trial treatments for COVID-19)?
- What is Dr. Ackerman saying about COVID-19?
First and foremost, all patients should follow relevant government advice on COVID-19.
Current government guidelines and government-provided information can be found here:
- The President's Coronavirus Guidelines for America
- Centers for Disease Control and Prevention (CDC) Coronavirus (COVID-19)
- Coronavirus.gov, a website provided by the CDC, the White House, and FEMA
- Most individual states have set up a COVID-19 webpage to provide information specific to each state. The CDC has provided these webpages here. Scroll down to "States Reporting Cases of COVID-19 to CDC*" and expand the list by clicking the "+" next to "States".
- World Health Organization (WHO) Coronavirus disease (COVID-19) Pandemic
Mayo Clinic has also set up a website to provide information about COVID-19. If you or a family member has an upcoming appointment, please check Mayo Clinic's Appointment and Visitor Restrictions page for more information as your visit may be rescheduled or changed to a non-face to face visit via either a teleconference or video consult.
It is important for everyone to monitor for symptoms of COVID-19. According to the CDC, symptoms may appear 2-14 days after exposure and usually include:
- Fever
- Cough
- Shortness of breath
Of course, these symptoms are not always a sign of concern as these can indicate anything from a common cold to the seasonal flu. If you or one of your family members has a genetic heart rhythm disorder and is believed to have been exposed to the coronavirus and develop symptoms, contact your healthcare provider or local COVID-hotline (if available) right away for medical advice.
Source: www.cdc.gov
COVID-19 and Genetic Heart Rhythm Disorders
We have been receiving many great questions from our patients regarding genetic heart rhythm disorders and COVID-19. We will address some of the most common questions below.
Most importantly, patients with genetic heart rhythm disorders (like LQTS, BrS, and CPVT) are not at higher risk of infection than anyone else. However, certain genetic heart muscle disorders (like ACM, DCM, and HCM) can be at increased risk of complications from COVID-19.
All patients, independent of their underlying heart rhythm disorder, should be cautious and practice proper handwashing and physical distancing (the 6-foot rule).
According to the Association for Inherited Cardiac Conditions (AICC), patients with genetic heart muscle disorders that are at an increased risk of complications once infected with COVID-19 are1:
- Dilated (DCM), arrhythmogenic (ACM), and hypertrophic (HCM) cardiomyopathy patients with LV impairment and/or symptomatic left heart failure.
- Arrhythmogenic cardiomyopathy (ACM) patients with RV impairment and/or symptomatic right heart failure.
- Symptomatic hypertrophic cardiomyopathy (HCM) with or without significant obstruction.
Patients with these disorders should obey strict physical distancing and should keep their social contacts to a minimum (family only if possible) to reduce the chance of contracting the virus.
Although we are not suggesting strict self-isolation for patients with Brugada syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), or long QT syndrome (LQTS), it is important to remember to follow the LQTS and BrS preventative measures if you do become ill. Because COVID-19 causes fever, it is especially important to aggressively treat fever (with acetaminophen) and persistently replace fluids and electrolytes. This is because fever increases the risk of arrhythmias in patients with these conditions.
For any patient with LQTS, the top 5 overarching preventative measures should always be observed:
- Avoidance of QT-prolonging medications whenever possible (www.crediblemeds.org or www.qtdrugs.org)
- Hydration and electrolyte replenishment, especially in the setting of vomiting and diarrheal illnesses
- Fever reduction in the setting of febrile illnesses and heat exhaustion avoidance
- Omega-3 fish oil supplementation as an optional supplement
- Learn CPR and obtain AED as part of a family's safety gear
For any patient with Brugada syndrome, the top 5 overarching preventative measures should always be observed:
- Avoidance of Brugada-aggravating medications (www.brugadadrugs.org)
- Hydration and electrolyte replenishment, especially in the setting of vomiting and diarrheal illnesses
- Fever reduction in the setting of febrile illnesses and heat exhaustion avoidance
- Avoidance of excess alcohol
- Strict avoidance of marijuana and cocaine
If you become ill and require medication and/or hospitalization, you must remember to tell your physicians and nurses that you have a genetic heart rhythm disorder. Work diligently with your physician to decide what the best course of action is for you. DO NOT STOP TAKING ANY MEDICATIONS WITHOUT THE DIRECTION OF YOUR PHYSICIAN!
Several antibiotics and antiviral medications are listed as QT-prolonging drugs and can increase the risk of arrhythmias. Furthermore, hydroxychloroquine and azithromycin have been suggested as possible treatments in the fight against the virus that causes COVID-19. We recommend any patient who is prescribed these medications to obtain or find their most recent QTc value (by 12-lead ECG, telemetry, or by smartphone-enabled mobile ECG devices). These therapies are potentially dangerous to patients with LQTS but not necessarily to patients with any of the other genetic heart conditions unless they have an elevated QTc. For patients with minor symptoms, we suggest it best to skip these medications. PLEASE DO NOT SELF-MEDICATE WITH CHLOROQUINE, HYDROXYCHLOROQUINE, OR AZITHROMYCIN.
For more information, please check out the possible COVID-19 therapies and the QTc algorithm and scientific paper with Dr. Ackerman as the senior author below.
What Dr. Ackerman is saying:
During recent weeks, Dr. Ackerman has been at the forefront of the discussion about different potential treatments for COVID-19. We've compiled these question-and-answer webinars, interviews, and discussions on COVID-19 below. During these sessions, many of your questions were asked and answered.
News Articles, Scientific Papers, Radio Programs, and More
The following links to news articles, scientific papers, radio programs, and other resources are also available on our Resources tab:
- Marked Up-Regulation of ACE2 in Hearts of Patients with Obstructive Hypertrophic Cardiomyopathy Implications for SARS-CoV-2-Mediated COVID-19 - Scientific paper by Dr. J. Martijn Bos published online in Mayo Clinic Proceedings on April 27, 2020
- Physicians, scientists and physician-scientists connect dots between heart disease, potential for worse COVID-19 outcomes - Article published by Mayo Clinic News Network on April 27, 2020
- Antimalarials widely used against COVID-19 heighten risk of cardiac arrest. How can doctors minimize the danger? - Article published by Science magazine and the American Association for the Advancement of Science (AAAS) on April 21, 2020
- Pediheart Podcast #114: Navigating the QTc Prolonging Potential of Possible Therapies for COVID-19 - Pediheart: Pediatric Cardiology Today Podcast, hosted by Dr. Robert H. Pass and featuring Dr. Michael Ackerman
- Mayo Clinic cardiologist: 'Inexcusable' to ignore hydroxychloroquine side effects - Article published by NBC News on April 7, 2020
- COVID-19 Miniseries Episode 10: How to Mitigate Drug-Induced Sudden Cardiac Death from Hydroxychloroquine - Mayo Clinic Talks Podcast, hosted by Dr. Darryl Chutka and featuring Dr. Michael Ackerman on April 6, 2020
- This Mayo Clinic Radio program from April 4th, 2020, shares the latest information on the COVID-19 (coronavirus) pandemic and features Dr. Abinash Virk, a Mayo Clinic infectious diseases specialist, Caroline Poland, a licensed mental health counselor, Dr. Michael Ackerman, a Mayo Clinic genetic cardiologist and director of the Windland Smith Rice Sudden Death Genomics Laboratory, and Dr. Joseph Sirven, a Mayo Clinic neurologist.
- Trump-touted malaria drug front and center in coronavirus treatment fight - Article published by The Washington Times on April 1, 2020
- SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes - Scientific paper by Dr. Arthur Wilde and Heart Rhythm Journal published online March 31, 2020
- Mayo warns drug touted by Trump as COVID-19 cure will "claim lives" - Article published by Post Bulletin on March 28, 2020
- Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19 - Scientific paper senior-authored by Dr. Michael J. Ackerman published online in Mayo Clinic Proceedings on March 25, 2020
- Guidance on patients at risk of drug-induced sudden cardiac death from off-label COVID-19 treatments - Article published by Mayo Clinic News Network on March 25, 2020
- Association for Inherited Cardiac Conditions (AICC) provided some guidance in advising patients with inherited cardiac conditions (ICCs) about COVID-19.
Videos: Q&As, Interviews, and Discussions with Dr. Ackerman
The following links will bring you to the videos about COVID-19 and other topics located on our Videos Archive tab.
- Facebook Live COVID-19 Vaccine and Updates Discussion (January 15, 2021)
- Facebook Live COVID-19 Update (July 24, 2020)
- ACE2 in Obstructive Hypertrophic Cardiomyopathy (HCM) & COVID-19 (April 27, 2020)
- Identifying risks of hydroxychloroquine for coronavirus treatment: Mayo Clinic cardiologist (April 27, 2020)
- Potential coronavirus treatment hydroxychloroquine comes with cardiac risk: Mayo Clinic genetic cardiologist (April 8, 2020)
- Special EP on EP Episode: QTc Monitoring With Drug Therapy During COVID-19 (April 7, 2020)
- Dr. Michael J. Ackerman & Dr. Arthur Wilde discuss COVID-19 and SADS Conditions (April 6, 2020)
- Q&A with Dr. Ackerman and CEO of SADS Alice Lara (April 3, 2020)
- SADS Conditions and COVID-19 with Dr. Michael J. Ackerman and Dr. Raymond Woosley (March 30, 2020)
- Mayo Clinic: Off-label drugs used for COVID-19 treatment come with cardiac risks (March 26, 2020)
- Navigating QTc Prolonging Potential of Pharmacotherapies for COVID-19 (March 25, 2020)
- Dr. Michael Ackerman discusses use of off-label COVID-19 treatments (March 25, 2020)
- Dr. Michael J. Ackerman answers your questions about COVID-19 and SADS Conditions (March 20, 2020)
Click on the links below to follow Dr. Ackerman and Mayo Clinic's Windland Smith Rice Genetic Heart Rhythm Clinic on Twitter for the most up-to-date information about COVID-19 and genetic heart rhythm disorders.